Part of the Group

CA 15-3 ELISA

Key Features and Values

– Same sample type can be used across all assays to simplify inclusion into routine serology work-up
– Ready to use reagents reduces hands-on time for assay preparation
– Long shelf life cost-effective solution by reducing wastage due to expired kits
– Suitable for inclusion on automated plate systems simplifies scale-up of test volume
– Supported by a complete panel of assays for supporting treatment monitoring of several forms of cancer

Product Description

Immunoenzymatic colorimetric method for the quantitative determination of CA 15-3 concentration in human serum or plasma. CA 15-3 ELISA is intended for laboratory use only.

Scientific Description
CA-15-3, is an abbreviation for cancer antigen 15-3.  CA 15-3 levels are most useful in following the course of treatment in women diagnosed with breast cancer, especially advanced breast cancer.  CA 15-3 levels are rarely elevated in women with early stage breast cancer.  Cancers of the ovary, lung and prostate may also raise CA 15-3 levels.  Elevated levels of CA 15-3 may be associated with non-cancerous conditions, such as benign breast or ovarian disease, endometriosis, pelvic inflammatory disease and hepatitis.
Pregnancy and lactation can also cause CA 15-3 levels to rise.  CA 15-3 is most useful for monitoring patients postoperatively for recurrence, particularly for metastatic diseases.  96% of patients with local and systemic recurrence have elevated CA 15-3, which can be used to predict recurrence earlier than radiological and clinical criteria.  A 25% increase in the serum CA 15-3 is associated with progression of carcinoma.  A 50% decrease in serum CA 15-3 is associated with response to treatment.  CA 15-3 is more sensitive than CEA in early detection of breast cancer recurrence.
In combination with CA-125, CA 15-3 has been shown to be useful in early detection of relapse of ovarian cancer.  CA 15-3 levels are also increased in colon, lung and hepatic tumours.
Publications

1. Aziz DC, et al Specialty Laboratories, (1991)
2. Aziz DC. A J Clin Pathol 98:105-11 (1992)
3. Aziz DC, et al J Clin Pathol 5:422-38 (1991)
4. Clark GM, et al N Engl J Med 320:627-33 (1989)
5. Elledge RM, et al Annu Rev Med 44:201-10 (1993)
6. Foekens JA, et al Cancer Res 50-3832-7 (1990)
7. Isola J, et al J Cell Biochem (Suppl 16D):101 (1992)
8. Kute TE, et al Cancer Res 52-198-203 (1992)
9. McGuire WL, et al J Natl Cancer Inst 82:1006-7 (1990)
10. Nicholson S, et al Br J Cancer 63:146-50 (1991)
11. Somerville JE, et al J Clin Pathol 45-16-20 (1992)
12. Ueronese S, et al Am J Clin Pathol 95:30-4 (1991)
13. Lotnicker M, et al Int. J. Biolog Markers 6:115 (1991)

Complementary Products

Download

Please enter your email address to download
Code: DKO055
Clinical Area:
Incubation: 60+60+15 min
Sensitivity: N/A
Specificity: N/A
Classification: IVD, CE
Number of Tests: 96
Sample Type: Serum/Plasma
Sample Volume: 20 µL (1:50 predilution)
Assay Range: 15-240 U/mL